HOME >> BIOLOGY >> NEWS
Unique international conference to focus on effectiveness, safety of medicinal herbs

By David Williamson
UNC-CH News Services

CHAPEL HILL -- Are medicinal herbs -- now extremely popular in the United States and abroad but only poorly regulated -- safe? Do they really work? How much should a person take in hope of producing the desired effect? Those are the chief questions top researchers will try to answer March 2-3 as the University of North Carolina at Chapel Hill hosts the first international scientific conference on "The Efficacy and Safety of Medicinal Herbs."

Speakers from Canada, England, Germany and the United States will discuss what's been confirmed about eight of the world's most widely used herbs at the university's Friday Center, according to conference co-chair Dr. Lenore Arab. Those herbs are garlic, ginseng, ginko biloba, comfrey, saw palmetto, feverfew, echinacea and St. John's wort.

"It's essential that health professionals know what we know about these products and what's still speculation so that they can give informed advice," said Arab, professor of epidemiology and nutrition at the UNC-CH schools of medicine and public health. "Right now, the public has stopped asking, and even if they were, most health professionals do not feel that they are in a position to give advice.

"As a result, the train is running wild down the track. People are self-medicating without any guidance. They might be taking extremely high, possibly dangerous, doses because they think more is better, or they may be getting so little that they're simply wasting their money."

As an example, she cited comfrey, which can cause liver damage and even liver failure. Banned in Canada and Europe, the herb is still widely available in U.S. health food stores.

Some 400 scientists, nutritionists and others are expected to attend the conference, Arab said.

Dr. Varro Tyler, professor and dean emeritus of pharmacy at Purdue University, will give the keynote address, "Herbal Medicine: From the
'"/>

Contact: David Williamson
David_Williamson@unc.edu
919-962-8596
University of North Carolina at Chapel Hill
13-Jan-2000


Page: 1 2

Related biology news :

1. Unique partnership between UH, FDA opens path for scientific exchange
2. Unique two-part macroemulsion offers new approach to cleaning up contaminated aquifers
3. Unique fleet of underwater vehicles to gather elusive environmental data
4. Unique feeding behavior discovered for snakes
5. Unique population of muscle stem cells found in mice
6. Unique social system found in famous Tsavo lions
7. Unique national park for orchids to be declared in Africa
8. Unique genetic alteration in presenilin 1 gene predisposes some Caribbean Hispanics to early-onset Alzheimers disease
9. Unique UNC study confirms suspected worldwide epidemic of childhood obesity
10. Scientists find just how discriminating a worm can be: Unique system of overlapping odor sensors discovered
11. Unique study reveals new details on how genes are transcribed

Post Your Comments:
(Date:8/19/2015)...  VOXX International Corporation (Nasdaq: VOXX ) ... Definitive Agreement to purchase the assets, inclusive of ... EyeLock through an acquiring entity.  Upon consummation of ... in the acquiring entity. The closing of the ...  Expanding on its existing supply chain and distribution ...
(Date:8/18/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/9dmm6l/global_biometric ... "Global Biometric Authentication & Identification Market: Focus On ... 2015-2020" report to their offering. ... market is expected to grow at an estimated ... generate over $25 billion (approximately) by 2020 as ...
(Date:8/12/2015)... Aug. 12, 2015   MedNet Solutions , an ... spectrum of clinical research, is proud to announce that ... comprehensive SaaS-based eClinical technology platform, has led the way ... two quarters of 2015.   Q2 2015 and Q1 ... measured by contract value sold in the company,s 15 ...
Breaking Biology News(10 mins):VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2MedNet Solutions Experiences Explosive Corporate Growth 2
(Date:9/2/2015)... -- Biovista Inc. is glad to announce ... science challenge, a global competition hosted by the Rare ... the latest life science innovations and technologies. ... capability to support Steven Laffoon and his ... Niemann-Pick Disease Type A (NPA), a rare and fatal ...
(Date:9/2/2015)... , Sept. 2, 2015  Neurotech Pharmaceuticals, ... enrolled in the multicenter Phase 2 clinical trial ... long-term treatment of recurrent subfoveal choroidal neovascularization secondary ... is a unique vascular endothelial growth factor (VEGF) ... implant. "This landmark proof-of-concept study will ...
(Date:9/2/2015)... -- Aytu BioScience, Inc. (OTCQB: AYTU), a specialty healthcare ... conditions, announced today that it has closed the final ... raising a total of $5.175 million, which includes proceeds ... Josh Disbrow , Chief Executive Officer of ... to be used to conduct clinical studies for both ...
(Date:9/2/2015)... , September 2, 2015 ... ("BioLight" or the "Company"), a firm that invests ... and cancer diagnostics, announced today that presentations highlighting ... will be delivered at the Ophthalmology Futures European ... Society of Cataract & Refractive Surgeons ("ESCRS"), both ...
Breaking Biology Technology:Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3
Cached News: